07:00 , Aug 22, 2016 |  BC Week In Review  |  Company News

Valeant Pharmaceuticals, Pharming deal

Pharming will pay Valeant $60 million up front and up to $65 million in sales milestones to reacquire North American commercialization rights to Ruconest conestat alfa. The recombinant human C1 esterase inhibitor is approved in...
01:15 , Nov 3, 2015 |  BC Extra  |  Financial News

Crinetics raises $40M series A

Crinetics Pharmaceuticals Inc. (San Diego, Calif.) raised $40 million in a series A round led by 5AM Ventures, Versant Ventures and Vivo Capital. The company is developing an oral, once-daily somatostatin agonist to treat acromegaly....
08:00 , Dec 15, 2014 |  BC Week In Review  |  Company News

Pharming, Santarus deal

Pharming received a $20 million milestone payment under a 2010 deal granting exclusive, North American commercialization rights to Santarus, which Salix Pharmaceuticals Ltd. (NASDAQ:SLXP, Raleigh, N.C.) acquired earlier this year. Salix recently launched of Ruconest...
08:00 , Nov 10, 2014 |  BioCentury  |  Finance

Convert resurgence

Biotechs have raised $5.6 billion through convertible debt financings so far this year, the highest amount since 2006. Two bankers attributed the resurgence to a growing mid-cap space that is taking advantage of low interest...
03:27 , Nov 7, 2014 |  BC Extra  |  Top Story

Salix hit on accounting turmoil

Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) plunged $53.05 (38%) to $85.50 in after-hours trading on Thursday on news its CFO had resigned and the company had retained outside counsel to investigate how it was accounting for inventory...
02:20 , Oct 9, 2014 |  BC Extra  |  Company News

FDA approves Uceris rectal foam

FDA approved an NDA for Uceris budesonide rectal foam from Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) to induce remission of mild to moderate distal ulcerative colitis (UC) extending up to 40 cm from the anal verge. Salix...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Company News

Ritter management update

Ritter Pharmaceuticals Inc. , Los Angeles, Calif.   Business: Gastrointestinal   Hired: Michael Step, a director, as CEO, formerly SVP of corporate development at Santarus Inc. , which Salix Pharmaceuticals Ltd. acquired; he succeeds Andrew...
07:00 , Sep 22, 2014 |  BC Week In Review  |  Clinical News

Ruconest conestat alfa: Phase II started

Pharming began a double-blind, placebo-controlled, crossover, international Phase II trial to evaluate once- or twice-weekly 50 IU/kg Ruconest for 12 weeks in about 30 HAE patients. Ruconest is approved in the U.S. and EU to...
07:00 , Aug 11, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Biodefense company Emergent BioSolutions Inc. (NYSE:EBS) was up $0.44 to $22.47 last week after submitting a BLA to FDA for Anthrax immune globulin IV (AIGIV) to treat inhaled anthrax. AIGIV is being developed...
07:00 , Jul 21, 2014 |  BC Week In Review  |  Clinical News

Rhucin regulatory update

Salix gained exclusive, North American commercialization rights to Ruconest through its January acquisition of Santarus Inc. , which received the rights from Pharming under a 2010 deal. Ruconest is already marketed in the EU for...